08 dec: Vestas-aktien ramt af Trump-udnævnelse af ny chef for EPA
08 dec: TDC vil købe obligationer tilbage for at reducere gæld - NY
08-12-2016 10:35:35

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
23 mar - 
Zealand Pharma: CFO sælger aktier for små 210.000 kr.
20 mar - 
Tirsdagens aktier: Mærsk trykket af direktørskifte i nø..
20 mar - 
Zealand Pharma når positive resultater med diabetes 1-m..
Relateret debat
20 apr - 
Et mere relevant spørgmål er: hvorfor købe et massivt u..
20 apr - 
Det går i den rigtige retning, men lidt for langs..
20 apr - 
Er der nogen som kan belyse spørgsmålet me..

Company announcement - No. 49 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 8 December 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 and the total proceeds to Zealand from the capital increase amounts to DKK 1,077,923.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,142,365 divided into 26,142,365 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe).  

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

49-16_1208 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 774036.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 apr
ZEAL
Zealand Pharma er i USA short'et  med 180.000 stk aktier og det er hvad der svarer til 10 fulde hand..
5
14 apr
ZEAL
ØU laver ikke en direkte beregning, men opremsede mange forskellige ting såsom fx salgs-milepælsbeta..
4
18 apr
ZEAL
Sjovt som du, Nada, ikke kan undvære at kommentere mine indlæg, nu hvor jeg lader dig fortælle om   ..
3
18 apr
ZEAL
Ja du er fuld af fup og fiduser 
3
18 apr
ZEAL
Solgt til Bioporto for en femmer 
3
18 apr
ZEAL
afnotering og tvangsindløsning.
3
16 apr
ZEAL
@EliotSpitzer   "Offentliggjorte korte nettopositioner" https://www.finanstilsynet.dk/da/Lovgivning/..
3
14 apr
ZEAL
Jeg mener - selv om jeg selv ejer aktien - at det er helt hen i vejret.   Fint nok, men jeg mener do..
3
20 apr
ZEAL
Et mere relevant spørgmål er: hvorfor købe et massivt underskudsgivende selskab i forventning om ove..
2
19 apr
ZEAL
GENERALFORSAMLING Zealand Pharma   I dag torsdag den 19. april kl. 15.00: Plesner Advokatpartnersels..
2

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

20-04-2018 12:49:56
Den amerikanske Vestas-konkurrent General Electric (GE) har solgt flere vindmøller i første kvartal, men selskabet melder om fortsat prispres i branchen. GE havde i de første tre måneder af 2018 en ordreindgang på 936 vindmøller mod 589 i samme periode sidste år. Selskabet oplyser ikke størrelsen på de solgte møller, men skriver i en kommentar, at det har haft en stærk vækst i USA målt på megawatt..

Brøndby-aktien banker til vejrs efter sejr over guldrival

20-04-2018 09:20:41
Aktien i Brøndby IF bliver sendt til vejrs med en stigning på 13,6 pct. til 1,25 kr. fredag morgen, efter at fodboldklubben torsdag aften vandt 3-2 på udebane over FC Midtjylland i Alka Superligaen.Med sejren fastholder Brøndby IF sin førsteplads i Alka Superligaen og har nu tre point ned til netop FC Midtjylland på andenpladsen. Der mangler at blive spillet seks runder, før sæsonen er slut i Alka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter
2
Fredagens aktier: Mærsk i fuld fart frem - Vestas og Bavarian i bund
3
Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald
4
Norden/Jyske: Aktien skal reagere positivt på takterne fra Baltic Dry
5
Mærsk-konkurrent køber stor aktiepost i DSV-rival

Relaterede aktiekurser

Zealand Pharma A/S 93,50 -0,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. april 2018 11:41:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180417.1 - EUROWEB1 - 2018-04-21 11:41:50 - 2018-04-21 11:41:50 - 1 - Website: OKAY